Viatris Inc. (VTRS)

NASDAQ: VTRS · USD

—

Dự phòng tiếng AnhVI

Hiển thị bản gốc tiếng Anh trong khi đang dịch

Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.

StockMarketAgent Research · Analyzed 2026-10-10

Our latest published analysis: VTRS rated Reduce

Viatris Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$15.9 / share

Potential value

$18.8 / share

Upside to FV

-9.8%

Moat

5.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$20.3B
P/E (forward)	6.4x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 6.4x
Market cap: $20.3B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$17.81B	$16.22B	$15.39B	$14.69B	$14.25B	-5.4%
Gross profit	$5.58B	$6.50B	$6.44B	$5.62B	$5.01B	-2.6%
Operating income	$-34.0M	$1.61B	$766.2M	$10.1M	$-2.66B	—
Net income	$-1.27B	$2.08B	$54.7M	$-634.2M	$-3.51B	—
EPS (diluted)	$-1.05	$1.71	$0.05	$-0.53	$-3.00	—
EBITDA	$4.48B	$6.43B	$3.52B	$2.64B	$-395.4M	—
R&D	$751.1M	$662.2M	$805.2M	$808.7M	$965.9M	+6.5%
SG&A	$4.53B	$4.18B	$4.07B	$4.10B	$3.79B	-4.3%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	—	—	—	—	—	—	Bán
ABNB	Airbnb, Inc.	—	—	—	—	—	—	Bán
ADBE	Adobe Inc.	—	—	—	—	—	—	Mua mạnh
ABBV	AbbVie Inc.	—	—	—	—	—	—	Bán
ABT	Abbott Laboratories	—	—	—	—	—	—	Giảm
ALGN	Align Technology Inc.	—	—	—	—	—	—	Giảm

Base and Bull scenarios

Base55%

Price target

$15.91

-9.8% from spot

The Base case assumes Viatris executes on management guidance of ~2% operational revenue growth, achieving over 100 new product approvals while maintaining operating margins around 16.5% to 18.5%. Operating cash flow of approximately $2.3B supports ongoing debt reduction, yielding a Fair value of $15.91.

Consolidated revenue growth moderates over the projection period following modest expansion in FY2026
Normalized operating margin expands steadily over the forecast period
Terminal P/E multiple expands modestly toward peer baseline levels
Annual free cash flow supports sustained debt paydown and modest share count contraction

Bull20%

Price target

$18.81

+6.6% from spot

The Bull case envisions accelerated commercialization of complex generics and specialty pipeline assets, such as meloxicam reaching peak sales potential up to $500M. Operating margins expand substantially and rapid deleveraging drives multiple re-rating toward peer levels.

Operating margins expand substantially driven by complex generics and proprietary specialty assets
Meloxicam reaches peak sales potential up to $500M with multi-year exclusivity
Terminal multiple expands toward peer levels like Baxter's 11.94x forward P/E
EPS compounding accelerates substantially above baseline rates annually

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($15.91). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	1.5%	1.8%	2.0%	2.3%	2.5%
8.1%	$16.5	$16.5	$16.5	$16.5	$16.5
8.6%	$16.2	$16.2	$16.2	$16.2	$16.2
9.1%	$15.9	$15.9	$15.9	$15.9	$15.9
9.6%	$15.6	$15.6	$15.6	$15.6	$15.6
10.1%	$15.3	$15.3	$15.3	$15.3	$15.3

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Forward P/E6.4

P25 n/aP50 n/aP75 n/a

Trailing P/E0

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

Deeper analysis on VTRS

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this VTRS report

What is the latest published VTRS stock rating?

Viatris Inc. is shown with Reduce in the latest published report, analyzed 2026-10-10. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full VTRS analysis?

The full latest published report, analyzed 2026-10-10, lives at /stocks/VTRS/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for VTRS?

The latest published report analyzed 2026-10-10 gives VTRS a fair value of USD 16 and a potential value of USD 19. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the VTRS page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-10). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ReduceVTRS · Fair value $15.9-9.8%

Read full analysis →

Category	Score	Reading
Valuation	3.0
Management	7.5
Balance Sheet	6.0
Profitability	1.5
Revenue Growth	4.5
Risk Assessment	6.5
Competitive Moat	5.5
Earnings Quality	3.0
Capital Efficiency	2.5

Viatris Inc. (VTRS)

Our latest published analysis: VTRS rated Reduce

Price

Financial snapshot

Fair-value bridge

Latest news · VTRS

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on VTRS

Frequently asked questions

Lịch sử xếp hạng